Literature DB >> 11748852

Nine novel mutations in NR0B1 (DAX1) causing adrenal hypoplasia congenita.

Y H Zhang1, B L Huang, K Anyane-Yeboa, J A Carvalho, R D Clemons, T Cole, B C De Figueiredo, M Lubinsky, D L Metzger, R Quadrelli, D R Repaske, S Reyno, L H Seaver, A Vaglio, G Van Vliet, L L McCabe, E R McCabe, J K Phelan.   

Abstract

X-linked adrenal hypoplasia congenita (AHC) is caused by mutations in the NR0B1 gene. This gene encodes an orphan member of the nuclear receptor superfamily, DAX1. Ongoing efforts in our laboratory have identified nine novel NR0B1 mutations in X-linked AHC patients (Y81X, 343delG, 457delT, 629delG, L295P, 926-927delTG, 1130delA, 1141-1155del15, and E428X). Two additional families segregate previously identified NR0B1 mutations (501delA and R425T). Sequence analysis of the mitochondrial D-loop indicates that the 501delA family is unrelated through matrilineal descent to our previously analyzed 501delA family. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748852     DOI: 10.1002/humu.1236

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  3 in total

Review 1.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

Review 2.  DAX1: Increasing complexity in the roles of this novel nuclear receptor.

Authors:  Edward R B McCabe
Journal:  Mol Cell Endocrinol       Date:  2007-01-08       Impact factor: 4.102

3.  Effect of Recombinant Gonadotropin on Testicular Function and Testicular Sperm Extraction in Five Cases of NR0B1 (DAX1) Pathogenic Variants.

Authors:  Jordan Teoli; Vincent Mezzarobba; Lucie Renault; Delphine Mallet; Hervé Lejeune; Pierre Chatelain; Frédérique Tixier; Marc Nicolino; Noël Peretti; Sandrine Giscard D'estaing; Béatrice Cuzin; Frédérique Dijoud; Florence Roucher-Boulez; Ingrid Plotton
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-30       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.